Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma - Quiz - MDSpire

Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma

  • By

  • Marta Canelo-Vilaseca

  • Mohamad Sabbah

  • Roberta Di Blasi

  • Caterina Cristinelli

  • Anna Sureda

  • Sophie Caillat-Zucman

  • Catherine Thieblemont

  • March 27, 2025

  • 0 min

Share

Original Source(s)

Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma

  • by Marta Canelo-Vilaseca, Mohamad Sabbah, Roberta Di Blasi, Caterina Cristinelli, Anna Sureda, Sophie Caillat-Zucman, Catherine Thieblemont

  • March 27, 2025

Related Content

Epstein-Barr virus associated diseases: Immune alterations and targeted approaches

Creation and internal assessment of a nomogram tailored for lymphoma to forecast venous thromboembolism risk: analysis of a retrospective cohort comprising 790 patients

Immune escape mechanisms and therapeutic advances in virus-associated hematological malignancies